Kashyap Choksi
Cardiovascular Disease · Thomasville, GANPI 1508000183
Payments from drug & device makers
Across 713 payments — averaging $396.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$143K
- AstraZeneca$90K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$21K
- Boehringer Ingelheim$18K
- Lilly USA, LLC$5K
- Novartis$971
- plus $5K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 150 | $143,049 |
| AstraZeneca | 132 | $90,448 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 40 | $20,852 |
| Boehringer Ingelheim | 42 | $18,044 |
| Lilly USA, LLC | 7 | $4,673 |
| Novartis | 63 | $971 |
| Johnson & Johnson | 47 | $764 |
| Pfizer | 55 | $682 |
| Amgen | 31 | $553 |
| Alnylam Pharmaceuticals Inc. | 21 | $448 |
| E.r. Squibb & Sons, L.L.C. | 29 | $412 |
| Abbott | 10 | $406 |
| Merck | 19 | $328 |
| Amarin Pharma, Inc. | 9 | $212 |
| Kowa Pharmaceuticals America, Inc. | 12 | $171 |
| Abiomed | 3 | $162 |
| Novo Nordisk | 8 | $145 |
| Cvrx, Inc. | 3 | $120 |
| Medtronic(2 entities) | 5 | $85 |
| Arbor Pharmaceuticals, Inc. | 5 | $81 |
| Esperion Therapeutics, Inc. | 5 | $70 |
| Regeneron Healthcare Solutions, Inc. | 4 | $69 |
| Sanofi-aventis U.S. LLC | 3 | $66 |
| Boston Scientific | 2 | $33 |
| Portola Pharmaceuticals, LLC | 2 | $31 |
| Kestra Medical Technology Services, Inc. | 1 | $21 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $14 |
| Amryt Pharma Holdings Ltd | 1 | $12 |
How this compares
$282,971 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Thomasville
- Narendra SinghJohns Creek$5.4M
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Naresh ParikhNorcross$2.8M
- Nicolas ChronosEatonton$2.4M
- Bobby KhanAtlanta$1.7M
- Hunter ChampionColumbus$1.5M
- David SuhTucker$1.1M
- Michael MorrisAtlanta$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.